Company news

Santhera Pharmaceuticals Holding AG news in 2026

Santhera Pharmaceuticals Holding AG's news releases, calls and decks from 2026, newest first.

View company

Santhera’s Licensing Partner, Nxera Pharma, Submits Marketing Authorization Application for AGAMREE® (Vamorolone) in South Korea

October 23, 2026

Santhera Expands Biomedica Agreement to Extend AGAMREE® (Vamorolone) Distribution Across Central Asia and the Caucasus

July 13, 2026

Santhera Announces Orphan Drug and Priority Review Designations for AGAMREE® (Vamorolone) in South Korea

June 2, 2026

Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors

April 30, 2026

Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy

April 28, 2026

Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025

April 28, 2026

Santhera Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU

April 27, 2026

Santhera Appoints Orlando Oliveira as Chief Executive Officer

April 23, 2026

Full Year 2025 Trading Update

March 12, 2026

Santhera Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth

March 10, 2026

AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscular Dystrophy

March 9, 2026

Santhera Announces Proposed Inclusion and Reimbursement of AGAMREE® (Vamorolone) within Spain’s National Health System for the Treatment of Duchenne Muscular Dystrophy

February 27, 2026

Santhera Appoints Stifel as Corporate Finance Advisor

February 10, 2026

Santhera Receives Swissmedic Approval of AGAMREE® (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy

January 15, 2026

Santhera Pharmaceuticals Receives Swissmedic Approval of AGAMREE® (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy

January 14, 2026

Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties

January 8, 2026

Calls in 2026

Decks in 2026